HK Stock Market Move | XUANZHUBIO-B(02575) rose more than 14%, more than 2.3 times the IPO price. The company is currently experiencing a commercial breakthrough period this year.

XuanzhuBio-B (02575) rose over 14% in the afternoon, reaching a high of 38.8 Hong Kong dollars, an increase of over 234% from the IPO price of 11.6 Hong Kong dollars. As of the time of writing, it had risen 12.12% to 38.12 Hong Kong dollars, with a turnover of 32.2915 million Hong Kong dollars. The prospectus shows that XuanzhuBio was spun off from the Hong Kong-listed company SIHUAN PHARM (00460), representing a typical "H split H" scenario. By the deadline for the last feasible date, XuanzhuBio had over ten drug assets actively in development, covering digestive system diseases, tumors, and non-alcoholic steatohepatitis (NASH), including three NDA approved assets, one drug project in the NDA registration stage, one drug project in Phase III clinical trials, four drug projects in Phase I clinical trials, and five already approved for IND. In the article "Dual-wheel drive + commercialization" of the three-horse carts, Xuanzhu Bio aims to become a new benchmark for innovative drugs in the Hong Kong market, emphasizing that with the support of the dual drive of digestion and tumors, Xuanzhu Bio will enter a period of commercial explosion in 2025. The two core tumor drugs, Pirloxitinib tablets and Darolutamide tablets, have been successively approved, together with another core variety, the proton pump inhibitor Anrilazole sodium, which was previously approved for listing. This forms a commercial "three-horse cart" product matrix, representing the company's core innovation and commercialization strategy being recognized by both the industry and the market.